Development of new antimicrobials for urogenital gonorrhea therapy: Clinical trial design considerations

Academic Article

Abstract

  • © 2019 The Author(s). Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. Gonorrhea remains a major public health challenge, and current recommendations for gonorrhea treatment are threatened by evolving antimicrobial resistance and a diminished pipeline for new antibiotics. Evaluations of potential new treatments for gonorrhea currently make limited use of new understanding of the pharmacokinetic and pharmacodynamic contributors to effective therapy, the prevention of antimicrobial resistance, and newer designs for clinical trials. They are hampered by the requirement to utilize combination ceftriaxone/azithromycin therapy as the comparator regimen in noninferiority trials designed to seek an indication for gonorrhea therapy. Evolving gonococcal epidemiology and clinical trial design constraints hinder the enrollment of those populations at the greatest risk for gonorrhea (adolescents, women, and persons infected with antibiotic-resistant Neisseria gonorrhoeae). This article summarizes a recent meeting on the evaluation process for antimicrobials for urogenital gonorrhea treatment and encourages the consideration of new designs for the evaluation of gonorrhea therapy.
  • Authors

    Published In

    Digital Object Identifier (doi)

    Pubmed Id

  • 22037428
  • Author List

  • Hook EW; Newman L; Drusano G; Evans S; Handsfield HH; Jerse AE; Kong FYS; Lee JY; Taylor SN; Deal C
  • Start Page

  • 1495
  • End Page

  • 1500
  • Volume

  • 70
  • Issue

  • 7